Moscow – Russian scientists say the country’s Sputnik V vaccine appears to be safe and effective against COVID-19, according to early results of advanced research published in a British medical journal on Tuesday. I will.
The news is boosting vaccines that are increasingly being purchased by governments around the world to stop the devastation caused by the coronavirus pandemic.
Researchers said the vaccine was about 91% effective, based on an autumn study involving about 20,000 people in Russia, which seems to prevent vaccinated individuals from becoming seriously ill with COVID-19. It was. However, it is unclear whether Sputnik V can stop the infection. The study was published online on The Lancet on Tuesday.
Scientists unrelated to the study acknowledged that the speed at which the vaccine was made and deployed led to criticism of Russia’s efforts for “unsightly speed, horn cutting, and lack of transparency.”
“But the results reported here are clear,” wrote British scientists Ian Jones and Polly Roy in an accompanying commentary. “Another vaccine is now available in the fight to reduce the incidence of COVID-19.”
The vaccine was approved by the Russian government on August 11th in many fanfares. President Vladimir Putin personally reported the news on national television, saying that one of his daughters had already received it. At that time, the vaccine was only tested by dozens of people, and the move caused criticism from domestic and foreign experts.
Kirill Dmitriev, CEO of the Russian Foreign Direct Investment Fund, which funded the development of Shot, called the study at Lancet “check and mate Russian vaccine critics.”
“Russia was right from the beginning,” he said.
Outside Russia, Sputnik V is licensed in more than 12 countries, including the former Soviet Republic of Belarus, Armenia and Turkmenistan, according to the fund. Latin American countries including Argentina, Bolivia and Venezuela. African countries such as Algeria, Serbia, Iran, Palestine and United Arab Emirates.
Vaccine batches have already been supplied to 6 countries. A spokesman for RDIF told The Associated Press that a total of more than 50 countries have submitted 2.4 billion applications.
The latest study is based on a study of about 20,000 people over the age of 18 at 25 hospitals in Moscow between September and November, three-quarters of which are Russian vaccines every 21 days. Was inoculated twice and the rest received placebo injections.
Serious side effects were rarely reported in both groups, with 4 deaths reported, but not believed to be the result of the vaccine.
More than 2,100 people over the age of 60 participated in this study, and the vaccine appeared to be about 92% effective. The study is underway, but in December the Russian Ministry of Health reduced the scale of the study from the planned 40,000 subjects to about 31,000 already enrolled volunteers, with developers ethics regarding the use of placebo shots. He said he was raising concerns.
Russian vaccines carry the coronavirus peplomer gene using a modified version of the common cold-causing adenovirus as a way to stimulate and react to the body in the event of COVID-19. I will. This is a technology similar to the vaccine developed by AstraZeneca and the University of Oxford. However, unlike AstraZeneca’s double-dose vaccine, Russians used a slightly different adenovirus for their second boost.
“This aims to promote a higher immune response to the target’spikes’ by using two slightly different jabs,” said an organism at the University of Reading, UK, unrelated to Russian research. Alexander Edwards, an associate professor of medical technology, said. He said that if you have two identical shots, your immune system may not be boosted that much from the second injection.
Roy, a professor of virology at the London School of Economics and Tropical Medicine, said there was no doubt about Russian vaccines anymore. She suggests that the high levels of antibody produced by Sputnik V can also protect against some of the more recently detected new COVID-19 mutants, but further research is needed to verify this. Said there is.
“Initially, I was concerned about what they were saying and thought they were getting too much publicity, but the data is now very powerful,” Roy said.
Sputnik V launched a large-scale vaccination campaign in Russia in December, with doctors and teachers first lined up. Last month Putin ordered the start of mass vaccination.
In early January, the Russian Foreign Direct Investment Fund stated that more than one million Russians had already been vaccinated. Some Russian media questioned the number, suggesting that it was much slower to deploy and that many Russian regions reported a small number of vaccinations.
Production of Sputnik V spans several countries, including India, South Korea, Brazil and China. “We will also manufacture vaccines in Kazakhstan and develop (produce) them in Belarus, Turkey, and perhaps Iran,” Dmitriev said, adding that production in China will begin at the end of the month.
Algeria will begin producing the Sputnik V vaccine “within the next few weeks,” said Camel Mansouri, head of the National Pharmaceutical Institution in Algeria, on Tuesday. Last week, the first batch of 50,000 batches arrived in Algeria.
According to the European Medicines Agency, the developers of Sputnik V recently sought advice on the data that must be submitted to obtain vaccine approval across the European Union in 27 countries.
The first shipment of Hungarian Sputnik V — 40,000 shipments — arrived on Tuesday, Foreign Minister Peter Sijart said on Facebook. Hungary will receive enough Sputnik V vaccine to treat 1 million people in the next three months.
Hungarian health authorities first approved the vaccine in the EU on 21 January, but the National Public Health Center needs to give final approval before the shots are distributed to the public.
The minister had the opportunity to blow up the EU’s own vaccination deployment, which is much slower than Israel, the United Kingdom, or the United States.
“Brussels’ centralized vaccine procurement has failed, endangering the lives of Europeans and jeopardizing the rapid resumption of the European economy,” Szijjarto said.
“We were the first, but probably not the only ones” in the EU to consider using the COVID-19 vaccine in Russia and China, he added.
Chen reported from Toronto. Contributed by Associated Press writer Aomar Ouali of Algeria, Lori Hinnant of Paris, and Justin Spike of Budapest, Hungary.
Follow all AP pandemic coverage at https://apnews.com/hub/coronavirus-pandemic, https://apnews.com/hub/coronavirus-vaccine, https://apnews.com/UnderstandingtheOutbreak
Copyright 2021 AP communication. all rights reserved. This material may not be published, broadcast, rewritten, or redistributed without permission.
Russian Sputnik V vaccine appears to be safe and effective
Source link Russian Sputnik V vaccine appears to be safe and effective